Video Experimental Relacionado

Updated: Aug 11, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Farmacocinética de R 82913 en pacientes con SIDA o complejo relacionado con el SIDA

G Pialoux¹, M Youle, B Dupont

¹Hôpital de l'Institut Pasteur, Paris, France.

Lancet (London, England)

|July 20, 1991

Resumen

R 82913, un nuevo medicamento, es prometedor para el tratamiento de las infecciones por VIH-1. Este estudio encontró que es seguro y eficaz en la reducción de los marcadores virales en pacientes con SIDA, lo que sugiere que se justifica una mayor investigación.

Área de la Ciencia:

Virología Virología.
Farmacología Farmacología.
Inmunología Inmunología.

Sus antecedentes:

El virus de la inmunodeficiencia humana 1 (VIH-1) sigue siendo un desafío significativo para la salud mundial.
El desarrollo de terapias antirretrovirales efectivas es crucial para el manejo de la infección por VIH-1 y el SIDA.
Los derivados de la tetrahidroimidazobenzodiazepinthiona (TIBO) representan una clase de compuestos con actividad antiviral potencial.

Objetivo del estudio:

Evaluar la seguridad y la eficacia preliminar de R 82913, un derivado de TIBO, en pacientes con SIDA o complejo relacionado con el SIDA.
Evaluar la tolerabilidad y el perfil farmacocinético de R 82913 en un estudio de aumento de dosis.
Investigar el impacto de R 82913 en marcadores virológicos clave, incluidos el antígeno p24 y el recuento de células OKT4.

Principales métodos:

Un estudio piloto de escalada de dosis que involucró a 22 pacientes diagnosticados con SIDA o complejo relacionado con el SIDA.
La administración intravenosa de R 82913 al día, con dosis que van desde 10 a 300 mg.
Monitoreo de la tolerabilidad del fármaco, los parámetros hematológicos y bioquímicos, las concentraciones plasmáticas del fármaco, el recuento de células OKT4 y los niveles de antígeno p24 durante un máximo de 50 semanas.

Principales resultados:

R 82913 fue bien tolerado en dosis de hasta 300 mg al día durante hasta 50 semanas, sin toxicidad observada.
Se observó un ligero aumento en el recuento medio de células OKT4 durante el segundo mes de tratamiento.
Se observó una reducción mediana significativa del 41% en la concentración del antígeno p24 durante el primer mes de tratamiento (p < 0,03).

Conclusiones:

R 82913 demuestra una potente actividad in vitro contra el VIH-1 y un perfil de seguridad favorable in vivo.
El fármaco redujo efectivamente los niveles del antígeno p24 del VIH-1 y mostró una tendencia a mejorar el recuento de células OKT4.
R 82913 y derivados relacionados de TIBO merecen una mayor investigación para el tratamiento de las infecciones por VIH-1.

Más Videos Relacionados

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Videos de Conceptos Relacionados

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Dosage Regimens: Partial Pharmacokinetic Parameters

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...

Pharmacokinetics: Drug–Drug Interactions

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship

For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...